Abstract
Until a few years ago, the prevailing view was that children should not be participants in clinical research trials because children were incapable of consenting to such nontherapeutic interventions and are particularly vulnerable to abuse. That view has undergone a significant shift in the last few years, particularly in the context of trials to test the safety and effectiveness of drugs. A number of events facilitated this change, including the widespread off-label distribution of drugs to children and developments in the AIDS epidemic. These social forces have shifted the core ethical question from whether children should be research subjects to when children should be research subjects.The presumption in favor of including children as research subjects for drug trials has manifested itself primarily through two different reforms: a 1997 federal statute and a set of regulations promulgated by the Food and Drug Administration (FDA) that recently became effective. Together they reflect the view that children deserve the same access to safe and effective therapies as adults.
Publisher
Cambridge University Press (CUP)
Subject
Health Policy,General Medicine,Issues, ethics and legal aspects
Reference216 articles.
1. 124. 65 Fed. Reg. at 19,777, col. 1. The most recent version of the document has been submitted for adoption by the countries' regulatory bodies, including the FDA. See International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, “The ICH Process for Harmonisation of Guidelines” (visited Oct. 31, 2000) (describing Steps 4 and 5).
2. 139. Id.
3. 84. See 45 C.F.R. §§ 46.101, 46.103 (1999).
4. “In Loco Parentis: Minimal Risk as an Ethical Threshold for Research upon Children,”;Ross;Hastings Center Report,1993
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献